The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside.
2015
The 18-kDa mitochondrial
translocator protein(TSPO) is known to be highly expressed in several types of cancer, including
gliomas, whereas expression in normal brain is low. TSPO functions in
gliomaare still incompletely understood. The TSPO can be quantified pre-operatively with
molecular imagingmaking it an ideal candidate for personalized treatment of patient with
glioma. Studies have proposed to exploit the TSPO as a transporter of chemotherapics to selectively target tumour cells in the brain. Our studies proved that
positron emission tomography(PET)-imaging can contribute to predict progression of patients with
gliomaand that
molecular imagingwith TSPO-specific ligands is suitable to stratify patients in view of TSPO-targeted treatment. Finally, we proved that TSPO in
gliomasis predominantly expressed by tumour cells. * AA, :
anaplastic astrocytoma; BBB, : blood-brain barrier; BPND, : non-displaceable
binding potential; CNS, : central nervous system; GAM, :
gliomaassociated microglia/macrophage; GBM, : glioblastoma; GFAP, :
Glial fibrillary acidic protein; HGG, : high-grade
glioma;
IDH1, :
isocitrate dehydrogenase1; LGA, :
low-grade astrocytomas; LGO, : low-grade
oligodendrogliomas; LGOA, : low-grade oligo-
astrocytoma; OA, : oligo-
astrocytoma; PET, :
positron emission tomography; rCBV, : relative cerebral blood volume; SRB, :
sulforhodamine Bcolorimetric; TCA, :
trichloroacetic acid; TSPO, :
translocator protein; WHO, : World Health Organization
Keywords:
-
Correction
-
Source
-
Cite
-
Save
33
References
15
Citations
NaN
KQI